Kronos Bio Stock Investor Sentiment
| KRON Stock | USD 1.02 0.03 2.86% |
About 61% of Kronos Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Kronos Bio suggests that many traders are alarmed. Kronos Bio's investing sentiment overview a quick insight into current market opportunities from investing in Kronos Bio. Many technical investors use Kronos Bio stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kronos |
Kronos Bio Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Kronos Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Kronos Bio that are available to investors today. That information is available publicly through Kronos media outlets and privately through word of mouth or via Kronos internal channels. However, regardless of the origin, that massive amount of Kronos data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kronos Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kronos Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kronos Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kronos Bio alpha.
Kronos Bio Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of tradable shares by Frisbee Allison of Kronos Bio subject to Rule 16b-3 | 09/18/2024 |
2 | Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer | 10/01/2024 |
3 | Acquisition by Charles Lin of 72900 shares of Kronos Bio at 0.96 subject to Rule 16b-3 | 10/15/2024 |
4 | Kronos Worldwide Inc Reports Q3 2024 GAAP EPS of 0. ... | 11/06/2024 |
5 | Kronos Worldwide Beats Q3 Earnings Estimates | 11/07/2024 |
6 | Kronos Worldwides Solid Profits Have Weak Fundamentals | 11/13/2024 |
7 | Kronos Bio downgraded by Piper Sandler, TD Cowen | 11/14/2024 |
8 | Kronos Bio downgraded by Piper Sandler, TD Cowen - MSN | 11/20/2024 |
9 | Biotech with Cambridge lab slashes 83 percent of staff, CEO departs | 11/27/2024 |
10 | Acquisition by Ridloff Elena of 17000 shares of Kronos Bio at 1.48 subject to Rule 16b-3 | 11/29/2024 |
11 | Wells Fargo to sell San Francisco headquarters, according to WSJ report | 12/03/2024 |
Check out Kronos Bio Hype Analysis, Kronos Bio Correlation and Kronos Bio Performance. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.